PubMed Health⌕ Search

Biomedical subjects

M M Odinak

Publications and source records attributed to M M Odinak.

At least 19 recordsLinked to original sources
PubMed2004

[Use of movalis in treatment of dorsopathy].

In regard to therapeutic effect of different medications used in dorsopathy treatment, non-steroid anti-inflammatory drugs rank first. Compounds selectively blocking COX-2 received special attention due to their minimal impact on COX-1 that provides good anti-inflammatory and analgesic effect with simultaneous dramatic reduction of ulcerogenic activity. One of the first drugs with such an action is Movalis (meloxicam). Thirty patients were divided into 2 groups, the first including 22 patients with vertebral diseases and musculotonic syndromes; patients of the second group (8) had a pain syndrome caused by disk herniation. During the first 3 days Movalis was administered in the form of injections (15 mg/day) and in the same doses in tablets for the following 20 days. After the treatment course, complete arrest of pain syndrome was observed in 33.3% patients, significant improvement--in 53.3% and insignificant effect--in 13.3%. Patients with reflex pain and musculotonic syndromes had a good analgesic effect after 3-day course of intramuscular injections, with the effect being mostly expressed in 8-10 days. Patients with diskogenic compressive radicular syndrome demonstrated a stable analgesic effect after a week of Movalis intake in tablet form. Movalis is well tolerated; side effects have occurred in 10 patients but they were minimal and did not lead to the change of medication dose or additional therapy.

Adult↗
PubMed2002

[Neurological complications of infectious endocarditis].

Of 204 patients with infectious endocarditis (IE) treated in the hospital in 1980-2000, 43(21.2%) developed neurological complications. These were: ischemic stroke (72.1%), hemorrhagic stroke (9.3%), both (7%), abscess and subarachnoidal hemorrhage (2.3% for each), meningitis (7%), toxic encephalopathy (11.6%). Neurological complications of IE arose prior to treatment and within the first week of antibacterial therapy in 63% cases, more frequently in the left carotid territory. Neurological complications in IE debute manifested acutely, pareses were more frequent than paralyses, with elevated temperature, low hemoglobin and red cell levels, leukocytosis. MRT detected 8 +/- 4.6 foci in the brain, CT--2 +/- 1.1, on the average. Lethality of IE patients with neurological complications reached 58.1% and was significantly higher than in those without such complications (14.9%, p < 0.001). Overall acturial survival 1 year after the discharge from the hospital was 94.4%, 5-year survival--61.1%, 10-year survival--11%.

Adolescent↗
PubMed2002

[New approaches to antioxidant therapy in multiple sclerosis].

For study of antioxidant therapy efficiency in relapsing-remitting multiple sclerosis we investigated group 1 (18 patients) treated with alpha-lipoic acid and group 2 (14 patients) who received complex of antioxidants and neuroprotectors with various mechanisms of action (oc-lipoic acid, Nicotinamide, Acetylcysteine, Triovit Beta-carotine, Alpha-tocopheryl acetate, Ascorbic acid, Selenium, Pentoxifylline, Cerebrolysin, Amantadine hydrochloride) during 1 month, 2 times a year. The treatment resulted in significant reduction (2-3 times) of relapse frequency in multiple sclerosis patients (especially in group 2) and decrease of required corticosteroid courses. After antioxidant therapy the content of lipid peroxide products was significantly reduced (most expressed in group 2). The improved method of multicomponent antioxidant and neuroprotective therapy can be considered as pathogenic threatment in relapsing-remitting multiple sclerosis.

Adult↗
PubMed2001

[Proton magnetic-resonance spectroscopy in remitting and secondary-progressive multiple sclerosis].

Proton magnetic-resonance spectroscopy (PMRS) was used to measure the levels of inositol/myoinositol (Ins), choline, creatine/phosphocreatine (Cr), glutamine/glutamate (Glx/Glx1), N-acetylaspartate (NAA), gamma-aminobutyric acid (GABA) and lipids were measured in the foci of demyelinization in the brains of 59 patients with multiple sclerosis (MS). Magnetic-resonance imaging was performed during a single investigation. A control group comprised 20 healthy individuals. PMRS revealed significant alterations in the levels of metabolite in all the patients as compared with the controls: decreases in NAA by 23-52%, in Cr by 12-21%, in choline by 15-26%; increases in Ins by 51-63%; as well as the appearance of lipids (up to 100%). In MS, there were reduction in NAA/Cr, NAA/choline, and NAA/choline/Cr ratios by 12-53; 10-19; and 57-82%, respectively. As compared with the remitting MS, secondary-progressive MS showed decreases in the content of NAA by 23-25%, NAA/(choline + Cr) by 48-54% and increases in the levels of Ins and lipids by 50-76%. In remitting MS, there was a strong correlation between the NAA/Cr ratio and the volume brain lesion. It is concluded that PMRS evaluated the extent, pattern and activity of demyelinization (by the levels of Ins, NAA, Cr, lipids) and the intensity of cerebral atrophy (by NAA levels, NAA/Cr ratio). The findings testify that there are neurochemical differences between remitting and secondary-progressive MS.

Adolescent↗
PubMed2001

[Immunogenetic cytokine restriction in multiple sclerosis].

Sixty eight patients with verified multiple sclerosis (MS) (mean EDSS score 3.1 +/- 1.0) and 50 healthy donors have been investigated. Thirty five patients had relapsing-remitting, 25--secondary progressive, 8--primary progressive course. The remission was in 38, decompensation--in 20, relapse--in 10 patients. Lymphocyte subpopulations were investigated using monoclonal antibodies (Moscow) to the following antigens: CD3 (T-lymphocytes), CD4 (T-helpers), CD8 (T-supressors), CD20 (8-lymphocytes), CD25 (IL-2 receptor), CD16 (natural killers), CD95 (activated cells ready to apoptosis). Cytokines and tumor necrosis factor-alpha (TNF-alpha) levels were measured using ELISA test. HLA antigens were investigated by standard lymphocytotoxic test. In MS we found a fall of CD3, CD4, CD8, CD20 and CD16, but an increase of CD4/CD8, CD95, CD25. The CD95 level correlated with CD4, CD4/CD8 and CD16. In MS spontaneous IL-2, IL-6, IL-8 and TNF-alpha production was raised and stimulated IL-6 and IL-8 secretion was reduced. IL-4, IL-6, IL-8, TNF-alpha and IL-1 beta serum production in vivo was elevated. We found an increase of CD3, CD4, CD16, CD25, but a decrease of IL-1 (p < 0.01) spontaneous production and IL-6, IL-8, TNF-a stimulated secretion in DR2(+) MS patients, comparing to DR2(-) patients and controls. In DR2(-) patients as compared to DR2(+) patients and controls, all lymphocyte subpopulations levels, especially CD8 (p < 0.001) one, were decreased, but spontaneous IL-8 (p < 0.01) production was increased. The data obtained indicate lymphocyte apoptosis activation, targeting promoted lymphocyte destruction, and suggest T helper type-1 reaction prevalence in MS.

Adolescent↗
PubMed2000

[Multiple sclerosis in Northern-West region of Russia: results of HLA-typing].

Distribution of antigens of A, B, DR loci of HLA system in standard lymphocytotoxic test was studied in 59 patients with a significant diagnosis of multiple sclerosis (MS) and in 138 healthy donors. In the patients elevated frequency of the next antigens was found as compared with the controls: A10 (37%; chi 2 = 6.31; p < 0.05; relative risk--RR = 2.34), B7 (37%; chi 2 = 4.62; p < 0.05; RR = 2.05), B13 (29%; chi 2 = 10.86; p < 0.01; RR = 3.59), B35 (17%; chi 2 = 4.27; p < 0.05; RR = 2.61), DR2 (68%; chi 2 = 11.61; p < 0.001; RR = 2.99), as well as DR6 (5%; chi 2 = 3.95; p < 0.05; RR = 7.34) and also DRw52 (24%; chi 2 = 27.49; p < 0.001; RR = 21.16). The highest value of etiologic fraction was found for DR2 antigen. Analysis of intralocus and extralocus combinations of antigens in MS revealed that significantly elevated frequency had only one combination--B7DR2 (25.4%; chi 2 = 9.77; p < 0.01; RR = 3.58), relative risk was higher for this combination than for each individual antigen separately: B7 (RR = 2.05), DR2 (RR = 2.99). Significant negative associations with a possible protective effect of separate alleles were established in MS for antigens HLA A2 (34%; chi 2 = 5.55; p < 0.05; RR = 0.47), A11 (7%; chi 2 = 4.66; p < 0.05; RR = 0.31), A30 (0%; chi 2 = 4.50, p < 0.05; RR = 0.01), B18 (8%; chi 2 = 4.55; p < 0.05; RR = 0.35), DR5 (59%; chi 2 = 10.17; p < 0.01; RR = 0.36). The most significant was a decrease of the frequency of DR5 antigen (p < 0.01). Patients with the recurrent course had prevailed antigens A11, B21, B35 and decreased frequencies of antigens A9, B13, DR7. However, only the difference in the frequency of DR7 (16% in remitting and 57% in progredient course, chi 2 = 10.02; p < 0.001; RR = 0.14) was significant.

Adolescent↗